Article

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib

2021-12-11

Abstract excerpt

Osimertinib sensitive and resistant NSCLC NCI-H1975 clones were used to model osimertinib acquired resistance in humanized mice and delineate potential resistance mechanisms. No new EGFR mutations or loss of the EGFR T790M mutation were found in resistant clones. Resistant tumors in humanized mice were initially partially responsive to osimertinib, then aggressive tumor regrowth occurred accompanied by an immunosu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d865a672-0ab1-5ab0-b2e9-ac17641bd366
DOI: 10.1101/2021.12.10.472153

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibDOI 10.1101/2021.12.10.472153Read

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.Semantic proximity Read

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation.Semantic proximity Read

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read

Acquired resistance mechanisms to osimertinib: The constant battle.Semantic proximity Read

Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.Semantic proximity Read

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read

Mechanisms of resistance to osimertinibSemantic proximity Read

Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC.Semantic proximity Read

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.Semantic proximity Read

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells.Semantic proximity Read

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Semantic proximity Read

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.Semantic proximity Read